| Literature DB >> 28767726 |
Sanjana Mahapatra1,2, Emily M Mace1,2,3, Charles G Minard4, Lisa R Forbes2,3, Alexander Vargas-Hernandez1,2, Teresa K Duryea3,5, George Makedonas1,2,3, Pinaki P Banerjee2, William T Shearer2,3, Jordan S Orange1,2,3,6.
Abstract
Natural killer (NK) cells are critical in immune defense against infected, stressed or transformed cells. Their function is regulated by the heterogeneous expression of a wide array of surface receptors that shape its phenotypic diversity. Although NK cells develop in the bone marrow and secondary lymphoid tissues, substantive differentiation is apparent in the peripheral blood including known age-related variation. In order to gain greater insight into phenotypic and functional variation within peripheral blood NK cells across age groups, we used multi-parametric, polyfunctional flow cytometry to interrogate the NK cell variability in 20 healthy adults and 15 5-10, 11-15 and 16-20 year-old children. We found that the normative ranges in both adults and children displayed great inter-individual variation for most markers. While the expression of several receptors did not differ, among those that did, the majority of the differences existed between adults and the three pediatric groups, rather than among children of different ages. Interestingly, we also identified variation in the individual expression of some markers by sex and ethnicity. Combinatorial analysis of NK cell receptors revealed intermediate subsets between the CD56bright and CD56dim NK cells. Furthermore, on examining the NK cell diversity by age, adults were discovered to have the lowest developmental diversity. Thus, our findings identify previously unappreciated NK cell subsets potentially distinguishing children from adults and suggest functional correlates that may have relevance in age-specific host defense.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28767726 PMCID: PMC5540415 DOI: 10.1371/journal.pone.0181134
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
NK cell phenotyping panels.
| Panel 1 | Panel 2 | Panel 3 | Panel 4 | Panel 5 |
|---|---|---|---|---|
| Activating receptors | Adhesion/ stimulatory receptors | Inhibitory receptors | Developmental markers | Cytokines and effector molecules |
| CD8 | CD16 | CD158a/ KIR2DL1 | IL-15Rα | Perforin D48 |
| DNAM-1 | CD8 | CD158b/ KIR2DL2-3 | CD117/ c-kit | Perforin δG9 |
| NKG2D | CD2 | CD158e/ KIR3DL1 | CD127 | Granzyme B |
| NKp30/ NCR3 | CD244/ 2B4 | KIR2DS4 | CD27 | CD107a/ LAMP-1 |
| NKp44/ NCR2 | CD18 | NKG2A | CD62L | TNFα |
| NKp46/ NCR1 | CD11a (LFA-1) | NKG2C | CD94 | IFNγ |
| CD69 | CD11b (Mac-1, CR3) | CD94 | CD122 | IL-5 |
| CD25 | CD11c (CR4) | KLRG1 | CD16 | IL-13 |
| CD54/ ICAM-1 | CD11b | IL-10 | ||
| CD28 | CD57 |
Fig 1Significant inter-individual variation of NK cell markers between age groups of healthy adults and children.
NK cells were defined using flow cytometry as CD3-CD45highCD56+ and gated above fluorescence minus one (FMO) controls for all NK cell markers (panels shown in Table 1). (A-E) Percentage of NK cells positively expressing markers without stimulation among four age groups. (F-J) Median fluorescent intensity (MFI) of NK cells with positive expression of markers without stimulation among 4 age groups. 5–10 y.o. (n = 15) (red); 11–15 y.o. (n = 15) (green); 16–20 y.o. (n = 15) (blue) and adults (n = 20) (black). All bars for Panels 1–4 are indicative of surface expression. Panel 5 markers except CD3, CD45, CD56 and CD107a were detected intracellularly as described in the Materials and methods section. All data shown is mean ± S.D. *p<0.05 among four age groups by Kruskal-Wallis and post-hoc comparison by Dunn test with Bonferroni adjustment.
Fig 2Short-term NK cell stimulation leads to significant receptor modulation.
NK cells were stimulated for 4 hours using PMA/ ionomycin and evaluated using flow cytometry using panels shown in Table 1. (A-B) Percentage difference from baseline of NK cells expressing markers after stimulation among 4 age groups. (C-D) Median fluorescent intensity (MFI) difference from baseline of NK cells with positive expression of markers after stimulation among four age groups. 5–10 y.o. (n = 15) (red); 11–15 y.o. (n = 15) (green); 16–20 y.o. (n = 15) (blue) and adults (n = 20) (black). All bars for Panels 1–4 are indicative of surface expression. Panel 5 markers except CD3, CD45, CD56 and CD107a were detected intracellularly as described in the Materials and methods section. All data shown is mean ± S.D. *p<0.05 among four age groups by Kruskal-Wallis and post-hoc comparison by Dunn test with Bonferroni adjustment.
Significantly different markers by frequency within CD56dim NK cells of healthy adults and children.
| Panel | NK subset | Adults (Mean ± SD) | 5–10 y.o. (Mean ± SD) | 11–15 y.o. (Mean ± SD) | 16–20 y.o. (Mean ± SD) | Other significant results |
|---|---|---|---|---|---|---|
| 10.31% ± 4.64 | 18.96% ± 7.06 | 20.39% ± 9.98 | 15.61% ± 10.16 | |||
| n.s. | ||||||
| 2.06% ± 0.97 | 6.58% ± 5.68 | 5.51% ± 4.84 | 5.93% ± 4.76 | |||
| 62.38% ± 20.41 | 36.92% ± 18.02 | 44.15% ± 16.15 | 45.86% ± 18.82 | |||
| n.s. | ||||||
| 67.32% ± 12.89 | 65.05% ± 11.79 | 59.46% ± 9.19 | 54.68% ± 17.20 | |||
| n.s. | n.s. | |||||
| 0.73% ± 0.54 | 1.36% ± 0.74 | 1.56% ± 0.88 | 4.36% ± 5.96 | |||
| 94.82% ± 8.85 | 98.8% ± 1.01 | 99.39% ± 0.63 | 99.27% ± 0.88 | |||
| 69.35% ± 14.49 | 65.52% ± 12.05 | 67.96% ± 13.63 | 76.80% ± 14.26 | 5–10 y.o. vs 16–20 y.o. | ||
| n.s. | n.s. | n.s. | ||||
| 99.50% ± 0.59 | 90.13% ± 8.34 | 89.77% ± 5.52 | 82.57% ± 13.85 | |||
| 16.90% ± 7.32 | 31.95% ± 11.01 | 34.71% ± 10.44 | 23.97% ± 11.28 | 11–15 y.o. vs 16–20 y.o. | ||
| n.s. | ||||||
| 0.65% ± 0.99 | 0.76% ± 0.58 | 1.18% ± 0.68 | 1.14% ± 1.36 | |||
| n.s. | n.s. | |||||
| 1.48% ± 1.70 | 5.22% ± 5.49 | 5.42% ± 7.71 | 7.11% ± 9.04 | |||
| n.s. | ||||||
| 0.85% ± 0.39 | 0.26% ± 0.35 | 0.32% ± 0.51 | 0.21% ± 0.22 | |||
| 91.65% ± 5.43 | 96.05% ± 1.76 | 94.83% ± 3.93 | 95.66% ± 2.78 | |||
| n.s. | ||||||
| 0.88% ± 0.68 | 0.28% ± 0.27 | 0.33% ± 0.39 | 0.28% ± 0.32 | |||
Mean values represent percentage of CD56dim NK cells expressing the relevant marker. Significantly different results between adults and the respective pediatric group are indicated. Other statistically significant results among 3 pediatric age groups are depicted in the last column. 5–10 y.o. (n = 15); 11–15 y.o. (n = 15); 16–20 y.o. (n = 15) and adults (n = 20).
*p<0.05 **p<0.01 and ***p<0.001 among four age groups by Kruskal-Wallis and post-hoc comparison by Dunn test with Bonferroni adjustment
Significantly different markers by MFI within CD56bright NK cells of healthy adults and children.
| Panel | NK subset | Adults (Mean ± SD) | 5–10 y.o. (Mean ± SD) | 11–15 y.o. (Mean ± SD) | 16–20 y.o. (Mean ± SD) | Other significant results |
|---|---|---|---|---|---|---|
| 2.13 ± 2.80 | 7.55 ± 2.46 | 7.42 ± 1.69 | 6.71 ± 1.76 | |||
| 4.9 ± 1.41 | 3.81 ± 1.81 | 3.06 ± 1.1 | 4.07 ± 1.70 | |||
| n.s. | n.s. | |||||
| 0.66 ± 2.54 | 5.82 ± 1.88 | 5.64 ± 2.00 | 4.16 ± 2.41 | |||
| 5.3 ± 1.06 | 3.32 ± 2.25 | 4.15 ± 2.54 | 4.82 ± 1.70 | 5–10 y.o. vs 16–20 y.o. | ||
| n.s. | n.s. | |||||
| 5.98 ± 19.38 | 2.74 ± 4.39 | 3.68 ± 3.3 | 4.59 ± 6.83 | |||
| 2.32 ± 0.96 | 9.51 ± 12.36 | 8.81 ± 10.58 | 8.01 ± 8.70 | |||
| n.s. | ||||||
| 13.57 ± 2.34 | 8.63 ± 1.42 | 8.61 ± 1.95 | 8.38 ± 1.87 | |||
| 10.41 ± 3.72 | 7.10 ± 2.39 | 6.63 ± 2.16 | 7.64 ± 2.42 | |||
| n.s. | ||||||
| 13.00 ± 2.34 | 11.55 ± 1.75 | 10.48 ± 3.23 | 9.32 ± 2.20 | |||
| n.s. | ||||||
| 12.60 ± 7.81 | 21.53 ± 7.28 | 20.22 ± 5.62 | 13.88 ± 8.89 | 5–10 y.o. vs 16–20 y.o. | ||
| n.s. | ||||||
| 35.04 ± 9.85 | 30.54 ± 5.95 | 25.95 ± 9.90 | 25.09 ± 8.33 | |||
| n.s. | ||||||
| 6.76 ± 3.45 | 3.67 ± 0.56 | 3.54 ± 0.43 | 4.40 ± 1.21 | |||
| n.s. | n.s. | |||||
| 6.13 ± 4.87 | 8.4 ± 3.35 | 11.08 ± 8.42 | 7.3 ± 2.50 | |||
| n.s. | ||||||
| 13.48 ± 5.17 | 9.35 ± 6.80 | 9.15 ± 5.98 | 10.70 ± 5.93 | |||
| n.s. | ||||||
| 9.30 ± 4.19 | 6.06 ± 3.29 | 5.31 ± 2.11 | 6.38 ± 2.34 | |||
| n.s. | ||||||
| 3.29 ± 2.55 | 6.41 ± 3.78 | 3.92 ± 1.56 | 3.11 ± 0.95 | 5–10 y.o. vs 16–20 y.o. | ||
| n.s. | n.s. | |||||
| 6.32 ± 2.52 | 11.58 ± 8.34 | 9.74 ± 4.59 | 11.9 ± 8.41 | |||
Mean values represent median fluorescent intensity (MFI) of CD56bright NK cells positively expressing the relevant marker. Significantly different results between adults and the respective pediatric group are indicated. Other statistically significant results among 3 pediatric age groups are depicted in the last column. 5–10 y.o. (n = 15); 11–15 y.o. (n = 15); 16–20 y.o. (n = 15) and adults (n = 20).
*p<0.05 **p<0.01 and ***p<0.001 among four age groups by Kruskal-Wallis and post-hoc comparison by Dunn test with Bonferroni adjustment.
Significantly different markers by MFI within CD56dim NK cells of healthy adults and children.
| Panel | NK subset | Adults (Mean ± SD) | 5–10 y.o. (Mean ± SD) | 11–15 y.o. (Mean ± SD) | 16–20 y.o. (Mean ± SD) | Other significant results |
|---|---|---|---|---|---|---|
| 0.83 ± 1.35 | 4.72 ± 0.77 | 4.75 ± 1.35 | 3.81 ± 1.77 | |||
| 6.15 ± 0.69 | 6.87 ± 0.56 | 6.83 ± 0.54 | 7.4 ± 1.36 | |||
| 4.25 ± 0.96 | 2.33 ± 0.49 | 2.58 ± 0.64 | 2.89 ± 0.53 | |||
| 1.50 ± 2.14 | 3.41 ± 1.23 | 3.68 ± 1.85 | 2.91 ± 1.23 | |||
| 0.14 ± 1.05 | 4.66 ± 0.96 | 4.60 ± 1.36 | 3.30 ± 1.59 | |||
| 6.09 ± 2.01 | 3.12 ± 1.80 | 3.84 ± 2.38 | 4.38 ± 1.51 | |||
| n.s. | ||||||
| 6.55 ± 0.77 | 7.02 ± 0.41 | 6.94 ± 0.43 | 7.54 ± 0.66 | 11–15 y.o. vs 16–20 y.o. | ||
| n.s. | n.s. | |||||
| 1.64 ± 1.96 | 2.82 ± 1.17 | 2.87 ± 1.65 | 1.93 ± 0.94 | |||
| n.s. | ||||||
| 2.60 ± 0.84 | 11.20 ± 13.59 | 10.69 ± 12.58 | 10.94 ± 12.39 | |||
| 14.66 ± 3.03 | 9.71 ± 1.73 | 9.53 ± 2.11 | 10.20 ± 2.80 | |||
| 10.69 ± 5.12 | 7.53 ± 2.07 | 6.82 ± 2.42 | 8.19 ± 1.62 | |||
| n.s. | n.s. | |||||
| 8.36 ± 3.15 | 4.94 ± 2.43 | 5.80 ± 3.42 | 8.26 ± 2.67 | 5–10 y.o. vs 16–20 y.o. | ||
| n.s. | 11–15 y.o. vs 16–20 y.o. | |||||
| 8.96 ± 1.09 | 6.28 ± 0.64 | 6.11 ± 0.96 | 5.81 ± 0.94 | |||
| 6.77 ± 4.69 | 5.63 ± 2.29 | 6.74 ± 2.96 | 8.58 ± 2.77 | 5–10 y.o. vs 16–20 y.o. | ||
| n.s. | n.s. | n.s. | ||||
| 3.11 ± 1.32 | 4.94 ± 1.54 | 4.83 ± 2.35 | 3.26 ± 1.44 | 5–10 y.o. vs 16–20 y.o. | ||
| n.s. | n.s. | |||||
| 8.80 ± 2.00 | 6.83 ± 2.66 | 6.63 ± 1.72 | 6.61 ± 1.80 | |||
| 1.28 ± 0.68 | 2.00 ± 0.57 | 1.93 ± 0.87 | 1.99 ± 0.75 | |||
| n.s. | ||||||
| 4.81 ± 2.16 | 6.55 ± 1.97 | 7.12 ± 2.01 | 5.57 ± 1.40 | |||
| n.s. | ||||||
| 11.47 ± 2.16 | 14.20 ± 2.94 | 14.30 ± 3.55 | 13.62 ± 3.96 | |||
| n.s. | ||||||
| 2.14 ± 1.20 | 3.04 ± 1.29 | 2.88 ± 0.65 | 3.16 ± 1.69 | |||
| 6.24 ± 3.07 | 3.50 ± 0.26 | 3.52 ± 0.44 | 4.33 ± 0.97 | 5–10 y.o. vs 16–20 y.o. and 11–15 y.o. vs 16–20 y.o. | ||
| n.s. | ||||||
| 27.31 ± 18.01 | 39.55 ± 7.01 | 37.35 ± 8.12 | 35.12 ± 8.66 | |||
| n.s. | n.s. | |||||
| 5.56 ± 1.72 | 9.29 ± 4.76 | 7.09 ± 1.72 | 8.97 ± 5.11 | |||
| n.s. | ||||||
| 9.10 ± 3.94 | 5.18 ± 2.54 | 5.51 ± 2.28 | 6.19 ± 1.78 | |||
| n.s. | ||||||
| 24.65 ± 14.67 | 44.11 ± 17.28 | 32.56 ± 10.34 | 37.15 ± 13.76 | |||
| n.s. | n.s. | |||||
| 6.39 ± 2.03 | 9.06 ± 1.92 | 8.15 ± 1.42 | 9.44 ± 3.20 | |||
Mean values represent median fluorescent intensity (MFI) of CD56dim NK cells positively expressing the relevant marker. Significantly different results between adults and the respective pediatric group are indicated. Other statistically significant results among 3 pediatric age groups are depicted in the last column. 5–10 y.o. (n = 15); 11–15 y.o. (n = 15); 16–20 y.o. (n = 15) and adults (n = 20).
*p<0.05 **p<0.01 and ***p<0.001 among four age groups by Kruskal-Wallis and post-hoc comparison by Dunn test with Bonferroni adjustment.
Significantly different markers by frequency within CD56bright NK cells of healthy adults and children.
| Panel | NK subset | Adults (Mean ± SD) | 5–10 y.o. (Mean ± SD) | 11–15 y.o. (Mean ± SD) | 16–20 y.o. (Mean ± SD) | Other significant results |
|---|---|---|---|---|---|---|
| 53.05% ± 17.14 | 67.44% ± 10.9 | 67.15% ± 14.96 | 61.69% ± 14.88 | |||
| n.s. | ||||||
| 80.17% ± 9.73 | 80.24% ± 11.19 | 76.00% ± 8.48 | 68.38% ± 12.11 | 5–10 y.o. vs 16–20 y.o. | ||
| n.s. | n.s. | |||||
| 7.06% ± 5.86 | 18.68% ± 16.82 | 18.68% ± 11.29 | 18.39% ± 12.69 | |||
| n.s. | ||||||
| 58.12% ± 16.66 | 33.67% ± 23.45 | 44.83% ± 26.90 | 55.78% ± 28.65 | |||
| n.s. | n.s. | |||||
| 84.33% ± 8.33 | 84.17% ± 11.29 | 79.03% ± 9.48 | 71.71% ± 13.12 | 5–10 y.o. vs 16–20 y.o. | ||
| n.s. | n.s. | |||||
| 49.53% ± 16.20 | 64.56% ± 10.24 | 61.36% ± 14.78 | 68.03% ± 13.78 | |||
| n.s. | ||||||
| 2.91% ± 3.00 | 4.24% ± 3.68 | 3.35% ± 2.41 | 10.76% ± 10.70 | |||
| n.s. | n.s. | |||||
| 85.55% ± 13.83 | 90.84% ± 8.88 | 92.59% ± 11.05 | 95.52% ± 6.01 | |||
| n.s. | n.s. | |||||
| 84.14% ± 10.05 | 88.89% ± 8.40 | 87.3% ± 8.62 | 91.73% ± 6.61 | |||
| n.s. | n.s. | |||||
| 76.97% ± 12.89 | 90.54% ± 8.18 | 83.83% ± 14.57 | 89.74% ± 5.61 | |||
| n.s. | ||||||
| 98.1% ± 1.23 | 95.51% ± 2.96 | 90.10% ± 10.10 | 91.32% ± 8.94 | |||
| n.s. | n.s. | |||||
| 4.98% ± 4.89 | 0.96% ± 1.84 | 1.77% ± 2.09 | 3.19% ± 4.39 | |||
| n.s. | n.s. | |||||
| 1.39% ± 1.95 | 8.9% ± 6.23 | 8.79% ± 8.03 | 8.82% ± 9.53 | |||
| 57.71% ± 24.94 | 87.80% ± 10.03 | 83.35% ± 9.10 | 81.38% ± 15.05 | |||
| 46.19% ± 24.80 | 75.10% ± 12.26 | 68.90% ± 11.28 | 69.98% ± 14.33 | |||
| 8.60% ± 6.89 | 2.34% ± 2.86 | 3.87% ± 4.92 | 6.43% ± 7.24 | |||
| n.s. | ||||||
| 38.06% ± 17.34 | 68.92% ± 17.34 | 47.29% ± 22.02 | 52.57% ± 20.71 | 5–10 y.o. vs 11–15 y.o. | ||
| n.s. | n.s. | |||||
| 25.61% ± 14.35 | 58.61% ± 19.79 | 38.47% ± 22.95 | 43.67% ± 21.86 | 5–10 y.o. vs 11–15 y.o. | ||
| n.s. | n.s. | |||||
| 6.02% ± 4.49 | 1.74% ± 2.35 | 1.56% ± 1.66 | 2.57% ± 3.74 | |||
Mean values represent percentage of CD56bright NK cells expressing the relevant marker. Significantly different results between adults and the respective pediatric group are indicated. Other statistically significant results among 3 pediatric age groups are depicted in the last column. 5–10 y.o. (n = 15); 11–15 y.o. (n = 15); 16–20 y.o. (n = 15) and adults (n = 20).
*p<0.05 **p<0.01 and ***p<0.001 among four age groups by Kruskal-Wallis and post-hoc comparison by Dunn test with Bonferroni adjustment.
Fig 3Variation in total NK cell marker expression by sex in a healthy population of adults and children.
All 65 donors were pooled and divided by sex. Percentage of NK cells with positive expression of CD2, CD54 and CD11c (A-C) and CD107a after stimulation (D). CD16 (B73.1 clone) and granzyme B incubated in absence of stimulation (E, G) or stimulated with PMA/ionomycin (F, H). All markers except granzyme were detected by surface staining. Each data point represents a donor; male (n = 30), female (n = 35). All data shown is mean ± S.D. compared by Mann-Whitney test.
Fig 4Variation in total NK cell marker expression by ethnicity in a healthy population of adults and children.
All 65 donors were pooled and divided by ethnicity. Percentage of NK cells with positive expression of 2B4 and CD16 (A-B). Granzyme B and NKp30 incubated in absence of stimulation (C, E) or stimulated with PMA/ionomycin (D, F). All markers except granzyme were detected by surface staining. Each data point represents a donor; Asian (n = 13); Black (n = 13); Hispanic (n = 17) and White (non-Hispanic) (n = 21). All data shown is mean ± S.D. compared by Kruskal-Wallis and post-hoc comparison by Dunn test with Bonferroni adjustment.
Highly significant phenotypic differences in combinatorial NK subsets between adults and children.
| Cell type | Panel | NK subset | Mean Value (Adults) % | Mean Value (Children) % | % Diff |
|---|---|---|---|---|---|
| Activating receptors (With stim) | DNAM-1+CD8-CD69+NKG2D-NKp30-NKp46-NKp44-CD25- | 11.2 | 3.9 | 7.3 | |
| DNAM-1+CD8-CD69+NKG2D-NKp30-NKp46+NKp44-CD25- | 4.87 | 1.1 | 3.77 | ||
| Activating receptors (With stim) | DNAM-1-CD8-CD69-NKG2D-NKp30+NKp46-NKp44-CD25- | 2.29 | 6.96 | 4.67 | |
| DNAM-1+CD8+CD69+NKG2D-NKp30-NKp46-NKp44-CD25- | 8.31 | 3.9 | 4.41 | ||
| Adhesion/ stimulatory receptors | CD16 3G8-CD11a+CD11b+CD11c+CD18-CD54+CD244+CD2+ | 7.74 | 1.27 | 6.47 | |
| CD16 3G8+CD11a+CD11b+CD11c+CD18+CD54+CD244+CD2+ | 14.95 | 36.97 | 22.02 | ||
| Adhesion/ stimulatory receptors | CD16 3G8+CD11a+CD11b+CD11c+CD18+CD54+CD244+CD2+ | 13.71 | 26.4 | 12.69 | |
| Developmental markers | CD16 3G8-CD11b+CD57-CD94+CD62L-CD27-CD117-IL-15Rα- | 8.25 | 3.55 | 4.7 | |
| Cytokines and effector molecules (No stim) | Perf D48-Perf δG9-Granzyme-CD107a-IFNγ-IL-5-IL-10-IL-13- | 25.37 | 11.31 | 14.06 | |
| Perf D48-Perf δG9-Granzyme+CD107a-IFNγ-IL-5-IL-10-IL-13- | 9.59 | 1.66 | 7.93 | ||
| Perf D48+Perf δG9+Granzyme-CD107a-IFNγ-IL-5-IL-10-IL-13- | 4.7 | 23.98 | 19.28 | ||
| Cytokines and effector molecules (With stim) | Perf D48+Perf δG9+Granzyme+CD107a+IFNγ-IL-5-IL-10-IL-13- | 1.71 | 5.74 | 4.03 |
Mean values represent percentage of CD56bright or CD56dim NK cells expressing the combinatorial NK subset shown. All pediatric age groups were pooled. Panels with subsets that significantly differ with p<0.0004 between adults (n = 20) and children (n = 45) are shown.
Highly significant phenotypic differences in combinatorial NK subsets between stimulated and unstimulated cells.
| Cohort | Cell type | Panel | NK subset | Mean Value (With stim) % | Mean Value (No stim) % | % Diff |
|---|---|---|---|---|---|---|
| CD56bright | Activating receptors | DNAM-1+CD8-CD69-NKG2D-NKp30+NKp46+NKp44-CD25- | 5.67 | 12.4 | 6.73 | |
| DNAM-1+CD8-CD69+NKG2D-NKp30-NKp46-NKp44-CD25- | 11.2 | 1.29 | 9.91 | |||
| DNAM-1+CD8-CD69+NKG2D-NKp30+NKp46-NKp44-CD25- | 8.52 | 1.22 | 7.3 | |||
| CD56dim | Activating receptors | DNAM-1-CD8-CD69-NKG2D-NKp30-NKp46-NKp44-CD25- | 4.37 | 10.83 | 6.46 | |
| DNAM-1+CD8-CD69+NKG2D-NKp30-NKp46-NKp44-CD25- | 11.18 | 4.53 | 6.65 | |||
| CD56bright | Activating receptors | DNAM-1+CD8-CD69-NKG2D-NKp30+NKp46+NKp44-CD25- | 10.03 | 14.11 | 4.08 | |
| DNAM-1+CD8-CD69+NKG2D-NKp30+NKp46-NKp44-CD25- | 6.16 | 1.19 | 4.97 | |||
| DNAM-1+CD8+CD69-NKG2D-NKp30+NKp46+NKp44-CD25- | 3.65 | 8.33 | 4.68 | |||
| CD56dim | Activating receptors | DNAM-1-CD8-CD69-NKG2D-NKp30-NKp46-NKp44-CD25- | 9.36 | 14.7 | 5.34 | |
| DNAM-1+CD8-CD69-NKG2D-NKp30-NKp46-NKp44-CD25- | 8.18 | 13.78 | 5.6 | |||
| CD56bright | Cytokines and effector molecules | Perf D48+Perf δG9+Granzyme+CD107a-IFNγ-IL-5-IL-10-IL-13- | 9.54 | 25.92 | 16.38 | |
| CD56dim | Cytokines and effector molecules | Perf D48+Perf δG9+Granzyme+CD107a-IFNγ-IL-5-IL-10-IL-13- | 32.02 | 69.08 | 37.06 | |
| CD56bright | Cytokines and effector molecules | Perf D48+Perf δG9-Granzyme-CD107a-IFNγ-IL-5-IL-10-IL-13- | 4.24 | 10.77 | 6.53 | |
| Perf D48+Perf δG9+Granzyme-CD107a-IFNγ-IL-5-IL-10-IL-13- | 9.38 | 23.98 | 14.6 | |||
| Perf D48+Perf δG9+Granzyme+CD107a-IFNγ-IL-5-IL-10-IL-13- | 16.96 | 39.22 | 22.26 | |||
| CD56dim | Cytokines and effector molecules | Perf D48+Perf δG9-Granzyme+CD107a-IFNγ-IL-5-IL-10-IL-13- | 13.14 | 3.89 | 9.25 | |
| Perf D48+Perf δG9+Granzyme+CD107a-IFNγ-IL-5-IL-10-IL-13- | 33.19 | 77.29 | 44.1 | |||
| Perf D48+Perf δG9+Granzyme+CD107a-IFNγ+IL-5-IL-10-IL-13- | 9.79 | 1.32 | 8.47 | |||
| Perf D48+Perf δG9+Granzyme+CD107a+IFNγ-IL-5-IL-10-IL-13- | 11.92 | 2.12 | 9.8 | |||
| Perf D48+Perf δG9+Granzyme+CD107a+IFNγ+IL-5-IL-10-IL-13- | 9.03 | 0.08 | 8.95 |
Mean values represent percentage of CD56bright or CD56dim NK cells expressing the combinatorial NK subset shown. All pediatric groups were pooled and all comparisons were made within adults (n = 20) or within children (n = 45). Panels with subsets that significantly differed at p<0.0001 between stimulated and unstimulated cells are shown.
Highly significant phenotypic differences in combinatorial NK subsets between CD56bright and CD56dim cells.
| Cohort | Panel | NK subset | Mean Value (CD56bright) % | Mean Value (CD56dim) % | % Diff |
|---|---|---|---|---|---|
| Activating receptors (No stim) | DNAM-1-CD8-CD69-NKG2D-NKp30-NKp46-NKp44-CD25- | 1.94 | 10.83 | 8.89 | |
| DNAM-1+CD8-CD69-NKG2D-NKp30-NKp46-NKp44-CD25- | 7.68 | 14.08 | 6.4 | ||
| DNAM-1+CD8-CD69-NKG2D-NKp30+NKp46+NKp44-CD25- | 12.4 | 1.72 | 10.68 | ||
| Activating receptors (No stim) | DNAM-1-CD8-CD69-NKG2D-NKp30-NKp46-NKp44-CD25- | 3.67 | 14.7 | 11.03 | |
| DNAM-1-CD8-CD69-NKG2D-NKp30+NKp46-NKp44-CD25- | 3.33 | 8.29 | 4.96 | ||
| DNAM-1+CD8-CD69-NKG2D-NKp30-NKp46-NKp44-CD25- | 5.48 | 13.78 | 8.3 | ||
| DNAM-1+CD8-CD69-NKG2D-NKp30+NKp46+NKp44-CD25- | 14.11 | 4.34 | 9.77 | ||
| DNAM-1+CD8-CD69-NKG2D+NKp30+NKp46+NKp44-CD25- | 4.79 | 0.27 | 4.52 | ||
| DNAM-1+CD8+CD69-NKG2D-NKp30+NKp46+NKp44-CD25- | 8.33 | 1.43 | 6.9 | ||
| Activating receptors (With stim) | DNAM-1-CD8-CD69-NKG2D-NKp30-NKp46-NKp44-CD25- | 2.86 | 9.36 | 6.5 | |
| DNAM-1-CD8-CD69-NKG2D-NKp30+NKp46-NKp44-CD25- | 3.02 | 6.96 | 3.94 | ||
| DNAM-1+CD8-CD69-NKG2D-NKp30+NKp46+NKp44-CD25- | 10.03 | 4.84 | 5.19 | ||
| Adhesion/ stimulatory receptors | CD16 3G8-CD11a+CD11b+CD11c+CD18+CD54+CD244+CD2+ | 18.29 | 1.76 | 16.53 | |
| CD16 3G8+CD11a+CD11b+CD11c+CD18+CD54-CD244+CD2- | 3.74 | 14.43 | 10.69 | ||
| Adhesion/ stimulatory receptors | CD16 3G8-CD11a+CD11b+CD11c+CD18+CD54+CD244+CD2+ | 28.57 | 1.8 | 26.77 | |
| CD16 3G8+CD11a+CD11b+CD11c-CD18+CD54+CD244+CD2+ | 3.95 | 11.28 | 7.33 | ||
| CD16 3G8+CD11a+CD11b+CD11c+CD18+CD54-CD244+CD2- | 1.25 | 10.36 | 9.11 | ||
| CD16 3G8+CD11a+CD11b+CD11c+CD18+CD54-CD244+CD2+ | 2.38 | 12.64 | 10.26 | ||
| CD16 3G8+CD11a+CD11b+CD11c+CD18+CD54+CD244+CD2- | 4.81 | 14.17 | 9.36 | ||
| CD16 3G8+CD11a+CD11b+CD11c+CD18+CD54+CD244+CD2+ | 36.97 | 26.4 | 10.57 | ||
| Inhibitory receptors | CD158a-CD158b-CD158e-KIR2DS4-CD94+NKG2A+NKG2C-KLRG1- | 33.3 | 8.35 | 24.95 | |
| Inhibitory receptors | CD158a-CD158b-CD158e-KIR2DS4-CD94-NKG2A-NKG2C-KLRG1- | 2.28 | 7.55 | 5.27 | |
| CD158a-CD158b-CD158e-KIR2DS4-CD94-NKG2A-NKG2C-KLRG1+ | 1.19 | 6.5 | 5.31 | ||
| CD158a-CD158b-CD158e-KIR2DS4-CD94+NKG2A+NKG2C-KLRG1- | 34.83 | 12.08 | 22.75 | ||
| CD158a-CD158b-CD158e-KIR2DS4-CD94+NKG2A+NKG2C-KLRG1+ | 6.27 | 11.87 | 5.6 | ||
| CD158a-CD158b-CD158e-KIR2DS4-CD94+NKG2A+NKG2C+KLRG1- | 5.57 | 0.4 | 5.17 | ||
| CD158a-CD158b-CD158e-KIR2DS4+CD94+NKG2A+NKG2C-KLRG1- | 6.67 | 1.42 | 5.25 | ||
| Developmental markers | CD16 3G8-CD11b+CD57-CD94+CD62L+CD27-CD117-IL-15Rα- | 15.36 | 0.28 | 15.08 | |
| CD16 3G8+CD11b+CD57-CD94-CD62L-CD27-CD117-IL-15Rα- | 1.38 | 14.64 | 13.26 | ||
| CD16 3G8+CD11b+CD57-CD94+CD62L-CD27-CD117-IL-15Rα- | 8.76 | 27.99 | 19.23 | ||
| CD16 3G8+CD11b+CD57-CD94+CD62L+CD27+CD117-IL-15Rα- | 16.54 | 1.66 | 14.88 | ||
| CD16 3G8+CD11b+CD57+CD94+CD62L-CD27-CD117-IL-15Rα- | 3.47 | 19.89 | 16.42 | ||
| Developmental markers | CD16 3G8-CD11b+CD57-CD94+CD62L+CD27-CD117-IL-15Rα- | 7.52 | 0.23 | 7.29 | |
| CD16 3G8-CD11b+CD57-CD94+CD62L+CD27+CD117-IL-15Rα- | 9.41 | 0.22 | 9.19 | ||
| CD16 3G8+CD11b+CD57-CD94-CD62L-CD27-CD117-IL-15Rα- | 2.4 | 14.33 | 11.93 | ||
| CD16 3G8+CD11b+CD57-CD94+CD62L-CD27-CD117-IL-15Rα- | 6.17 | 19.81 | 13.64 | ||
| CD16 3G8+CD11b+CD57-CD94+CD62L+CD27-CD117-IL-15Rα- | 19 | 12.8 | 6.2 | ||
| CD16 3G8+CD11b+CD57-CD94+CD62L+CD27+CD117-IL-15Rα- | 19.18 | 2.38 | 16.8 | ||
| CD16 3G8+CD11b+CD57+CD94-CD62L-CD27-CD117-IL-15Rα- | 2.28 | 10.33 | 8.05 | ||
| CD16 3G8+CD11b+CD57+CD94+CD62L-CD27-CD117-IL-15Rα- | 5.36 | 14.32 | 8.96 | ||
| Cytokines and effector molecules (No stim) | Perf D48-Perf δG9-Granzyme-CD107a-IFNγ-IL-5-IL-10-IL-13- | 25.37 | 1.02 | 24.35 | |
| Perf D48+Perf δG9+Granzyme+CD107a-IFNγ-IL-5-IL-10-IL-13- | 25.92 | 69.08 | 43.16 | ||
| Cytokines and effector molecules (No stim) | Perf D48-Perf δG9-Granzyme-CD107a-IFNγ-IL-5-IL-10-IL-13- | 11.31 | 1.3 | 10.01 | |
| Perf D48+Perf δG9-Granzyme-CD107a-IFNγ-IL-5-IL-10-IL-13- | 10.77 | 1.08 | 9.69 | ||
| Perf D48+Perf δG9+Granzyme-CD107a-IFNγ-IL-5-IL-10-IL-13- | 23.98 | 2.07 | 21.91 | ||
| Perf D48+Perf δG9+Granzyme+CD107a-IFNγ-IL-5-IL-10-IL-13- | 39.22 | 77.29 | 38.07 | ||
| Cytokines and effector molecules (With stim) | Perf D48-Perf δG9-Granzyme-CD107a-IFNγ-IL-5-IL-10-IL-13- | 20.06 | 1.05 | 19.01 | |
| Perf D48-Perf δG9-Granzyme+CD107a-IFNγ-IL-5-IL-10-IL-13- | 11.16 | 0.81 | 10.35 | ||
| Perf D48+Perf δG9+Granzyme+CD107a-IFNγ-IL-5-IL-10-IL-13- | 9.54 | 32.02 | 22.48 | ||
| Perf D48+Perf δG9+Granzyme+CD107a-IFNγ+IL-5-IL-10-IL-13- | 2.03 | 12.14 | 10.11 | ||
| Cytokines and effector molecules (With stim) | Perf D48-Perf δG9-Granzyme-CD107a-IFNγ-IL-5-IL-10-IL-13- | 12.08 | 1.24 | 10.84 | |
| Perf D48-Perf δG9-Granzyme+CD107a-IFNγ-IL-5-IL-10-IL-13- | 6.35 | 0.33 | 6.02 | ||
| Perf D48+Perf δG9-Granzyme+CD107a-IFNγ-IL-5-IL-10-IL-13- | 3.51 | 13.14 | 9.63 | ||
| Perf D48+Perf δG9+Granzyme-CD107a-IFNγ-IL-5-IL-10-IL-13- | 9.38 | 1.1 | 8.28 | ||
| Perf D48+Perf δG9+Granzyme+CD107a-IFNγ-IL-5-IL-10-IL-13- | 16.96 | 33.19 | 16.23 | ||
| Perf D48+Perf δG9+Granzyme+CD107a-IFNγ+IL-5-IL-10-IL-13- | 3.06 | 9.79 | 6.73 | ||
| Perf D48+Perf δG9+Granzyme+CD107a+IFNγ-IL-5-IL-10-IL-13- | 5.74 | 11.92 | 6.18 | ||
| Perf D48+Perf δG9+Granzyme+CD107a+IFNγ+IL-5-IL-10-IL-13- | 3.32 | 9.03 | 5.71 |
Mean values represent percentage of CD56bright or CD56dim NK cells expressing the combinatorial NK subset shown. All pediatric groups were pooled and all comparisons were made within adults (n = 20) or within children (n = 45). Panels with subsets that significantly differed at p<0.0001 between CD56bright and CD56dim NK cells are shown.
Most relevant markers and combinatorial subsets in unstimulated NK cells.
| Value | NK cell type | Distinguishing subset/ marker | 5–10 y.o. | 11–15 y.o. | 16–20 y.o. |
|---|---|---|---|---|---|
| Total | ↑ | ||||
| CD56dim | NKp46 | ↑ | |||
| CD62L | ↑ | ↑ | |||
| CD56bright | Perforin | ↑↑↑ | |||
| Perf D48-Perf δG9-Granzyme-CD107a-IFNγ-IL-5-IL-10-IL-13- | ↓ | ||||
| ↑↑ | |||||
| Total | NKp46 | ↑↑ | ↑↑ | ↑↑ | |
| CD56dim | CD69 | ↓ | |||
| 2B4 | ↑↑ | ↑↑ | ↑↑ | ||
| CD11c | ↓ | ||||
| CD158a | ↑ | ||||
| CD62L | ↑ | ||||
| CD107a | ↑ | ↑ | |||
| IFNγ | ↓ | ↓ | |||
| CD56bright | 2B4 | ↑↑ | |||
| CD107a | ↑ | ||||
(A) Arrows represent percent change in NK cells expressing the marker or combinatorial subset shown with adults as baseline. Each marker/ subset has a percent change of >10%, fold change >0.4 and p<0.01 from adults. Those age groups that did not fulfill each of these criteria have been left blank. One arrow = percent change of 10–19%; two arrows = percent change of 19–28%; three arrows = percent change of 28–37%. (B) Arrows represent fold change in NK cells expressing the marker shown with adults as baseline. Each marker has a fold change >0.4 and p<0.01 from adults. Those age groups that did not fulfill each of these criteria have been left blank. One arrow = fold change of 0.4–2; two arrows = fold change of 2–5.
Most relevant markers and combinatorial subsets in stimulated NK cells.
| Value | NK cell type | Distinguishing marker | 5–10 y.o. | 11–15 y.o. | 16–20 y.o. | Adults |
|---|---|---|---|---|---|---|
| CD56dim | CD69 | ↑↑ | ↑↑↑ | |||
| CD56bright | CD69 | ↑↑ | ↑↑↑↑ | |||
| Total | NKp46 | <0.4↓ | <0.4↓ | <0.4↓ | ↓ | |
| CD56dim | CD69 | <0.4↑ | ↑ | ↑ | ||
| IFNγ | ↑ | ↑ | ↑ | |||
| CD56bright | CD107a | <0.4↑ | <0.4↓ | ↑ | <0.4↑ | |
| IFNγ | ↑ | <0.4↑ | ||||
(A) Arrows represent percent change in NK cells expressing the marker shown with unstimulated cells of the respective age group as baseline. Each marker has a percent change of >10% and fold change >0.4 from unstimulated cells. Only those markers that significantly differed at p<0.01 between stimulated NK cells of adults and the respective pediatric groups were considered. Those age groups that did not fulfill each of the above criteria have been left blank. One arrow = percent change of 10–19%; two arrows = percent change of 19–28%; three arrows = percent change of 28–37%; four arrows = percent change of 37–46%. (B) Arrows represent fold change in NK cells expressing the marker shown with unstimulated cells of the respective age group as baseline. Only those markers that significantly differed at p<0.01 between stimulated NK cells of adults and the respective pediatric groups were considered. Those age groups that did not significantly differ have been left blank. Markers with a fold change <0.4 from unstimulated cells but p<0.01 from adults are indicated accordingly. One arrow = fold change of 0.4–2.
Fig 5Clustering analysis of NK cell subsets using SPADE demonstrates phenotypic differences in healthy adults and children.
Each SPADE plot illustrates the concatenated NK cell data from several individuals and each node corresponds to the percentage of NK cells. Color of each node represents signal intensity (see scale) and size represents frequency. The regions of the plot (grey) were characterized by sequentially defining expression of each panel marker by signal intensity in separate SPADE plots. Individual markers defining entire regions are shown in the leftmost plot and combinatorial NK subset regions are indicated in the rightmost plot. (A) NK cells expressing activating receptors without stimulation among 5–10 y.o. (n = 15), 11–15 y.o. (n = 15), 16–20 y.o. (n = 15) and adults (n = 8) respectively. (B) NK cells expressing adhesion/ stimulatory receptors among 5–10 y.o. (n = 14), 11–15 y.o. (n = 14), 16–20 y.o. (n = 15) and adults (n = 12) respectively. (C) NK cells expressing inhibitory receptors among 5–10 y.o. (n = 15), 11–15 y.o. (n = 15), 16–20 y.o. (n = 15) and adults (n = 16) respectively. (D) NK cells expressing developmental markers among 5–10 y.o. (n = 13), 11–15 y.o. (n = 11), 16–20 y.o. (n = 9) and adults (n = 12) respectively. (E) NK cells expressing cytokines and effector molecules without stimulation among 5–10 y.o. (n = 15), 11–15 y.o. (n = 15), 16–20 y.o. (n = 15) and adults (n = 8) respectively.
Fig 6Quantification of NK cell diversity based on combinatorial expression of individual receptors.
Inverse Simpson indices are indicated for each panel and stratified by age group. Index values are representative of total number of distinct panel-wise combinatorial NK subsets found in each donor (diversity). The combinatorial subsets were previously computed using treeplot analysis. All data shown is median ± S.D. 5–10 y.o. (n = 15) (red); 11–15 y.o. (n = 15) (green); 16–20 y.o. (n = 15) (blue) and adults (n = 20) (black).